Cemdisiran’s Potential to Reduce Hospitalizations in Myasthenia Gravis

Symptom improvement is an important goal in generalized myasthenia gravis (gMG), but hospitalization and myasthenic crisis can reveal additional consequences of the disease. In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses hospitalization findings from the NIMBLE trial evaluating investigational cemdisiran.

Habib explains that myasthenic crisis represents the most severe manifestation of myasthenia gravis. Preventing impending crisis and keeping patients out of the hospital are important treatment goals, particularly for older individuals with other medical conditions. For patients who require inpatient care, reducing the duration of hospitalization also matters.

These events are relatively uncommon, which can make them difficult to evaluate during the limited observation periods of clinical trials. Habib emphasizes that hospitalization outcomes provide useful context alongside measures of symptoms and daily functioning, even when they are not the primary focus of a study.

Discussing NIMBLE’s 24-week double-blind treatment period, Habib describes numerically fewer patients experiencing worsening disease that progressed to impending myasthenic crisis or crisis with cemdisiran compared with placebo. He also notes fewer hospitalizations overall and a numerically shorter duration of hospitalization in the cemdisiran group.

However, Habib cautions that these observations involve small numbers of events. He characterizes the findings as encouraging and supportive rather than definitive evidence that treatment will prevent hospitalization in an individual patient. The distinction is important when communicating the results to clinicians and patients.

For pharmacists following developments in gMG treatment, the discussion highlights why evaluating a potential therapy requires attention to outcomes beyond symptom scores. Hospitalization findings may help clarify the broader burden of disease, but their interpretation must account for study duration, event frequency, and the role of these measures within the trial. Habib’s perspective places the findings within that clinical context while acknowledging the uncertainty that remains.